IONS Form 4: CEO/Director Acquires 189 Shares, Restricted Until March 2026

Rhea-AI Filing Summary

Brett Monia, who is listed as both a director and the Chief Executive Officer of Ionis Pharmaceuticals, purchased 189 shares of Ionis Pharmaceuticals, Inc. common stock on 08/29/2025 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan at a per-share price of $27.71. Following the transaction the filing reports 180,009 shares beneficially owned. The purchased shares are subject to a sale restriction and may not be sold until 03/02/2026. The Form 4 was signed by an attorney-in-fact on behalf of Brett Monia on 09/03/2025.

Positive

• Insider acquisition of 189 shares at $27.71 showing CEO/director participation in company equity
• Total beneficial ownership reported as 180,009 shares following the transaction
• Purchase executed under the company’s Amended and Restated 2000 Employee Stock Purchase Plan

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO/director acquired company shares through the employee purchase plan; transaction is routine and restricted until March 2026.

The Form 4 documents a non-derivative acquisition of 189 common shares at $27.71 per share under the company’s ESPP. The filing shows total beneficial ownership of 180,009 shares after the purchase. The shares are subject to a holding restriction until 03/02/2026, indicating they were purchased under plan limits or blackout/holding provisions. The disclosure was executed by an attorney-in-fact on 09/03/2025. Based solely on the filing, this is a standard employee purchase disclosure with no additional context on intent or material change to ownership percentages.

Corporate Governance Expert

TL;DR: Insider purchase by CEO/director via ESPP is disclosed properly and includes a post-acquisition holding restriction.

The report identifies Brett Monia as both a director and the Chief Executive Officer and records an ESPP purchase of 189 shares. The filing notes the shares cannot be sold until 03/02/2026, which is explicitly stated in the explanation. The Form 4 was completed and signed by an authorized attorney-in-fact, meeting filing formalities. The document contains no information about changes to board composition, compensation terms, or other governance actions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Monia Brett P

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock	189	$27.71	$5K

Holdings After Transaction: Common Stock — 180,009 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 29, 2025. These shares may not be sold until March 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 09/03/2025 - 06:30 PM Learn about SEC filing dates

FAQ

What did Ionis Pharmaceuticals (IONS) insider Brett Monia purchase?

Brett Monia purchased 189 shares of Ionis Pharmaceuticals common stock under the company’s ESPP at $27.71 per share on 08/29/2025.

How many shares does Brett Monia beneficially own after the transaction?

The Form 4 reports that Brett Monia beneficially owns 180,009 shares after the reported purchase.

Are there any sale restrictions on the purchased shares?

Yes. The filing states the shares may not be sold until 03/02/2026.

Who signed the Form 4 for Brett Monia and when?

The Form 4 was signed by Patrick R. O'Neil, attorney-in-fact for Brett Monia on 09/03/2025.

Under what plan were the shares purchased?

The shares were purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		J		189(1)	A	$27.71	180,009	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 29, 2025. These shares may not be sold until March 2, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett Monia	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.